Advertisement

Indian Journal of Microbiology

, Volume 59, Issue 2, pp 188–192 | Cite as

Pattern of Antimicrobial Sensitivity in Microbiologically Documented Infections in Neutropenic Patients with Haematological Malignancies: A single Center Study

  • Aisha Jamal
  • Naveena Fatima
  • Sajjad Shaikh
  • Bushra Kaleem
  • Qurratul Ain Rizvi
  • Uzma Zaidi
  • Munira Borhany
  • Tahir ShamsiEmail author
Original Research Article
  • 32 Downloads

Abstract

Febrile neutropenia is a medical emergency that complicates the clinical course and treatment of haematological malignancies, significantly enhancing the financial burden and worsening the overall outcome. This study was carried out to evaluate the efficacy of institution’s current first-line antibiotic regimen for febrile neutropenia in view of recent spectrum of institution’s local flora and its susceptibility pattern. 163 episodes of microbiologically documented infections in 110 adult patients were studied over a period of 1 year. Of 110 patients, 61 patients were male. The mean age of the patient population, mean absolute neutrophil count and temperature as documented were 30.1 years (SD ± 16.8), 450 cells/ul, and 101.9 °C respectively. Gram-negative and gram-positive organisms accounted for 79% and 21% of the febrile neutropenic infections respectively. E. coli and Staphylococcus aureus were the most common gram positive and gram negative pathogens respectively. A susceptibility pattern of > 60% was documented for all the gram negative pathogen’s associated febrile neutropenic infections for the current first-line antibiotic combination of Piperacillin/Tazobactum and Amikacin. Comparative analysis of results with the institutional data of 2015 study revealed no statistically significant difference in the resistance pattern of the organisms hence, validating the persistent use of Piperacillin/Tazobacum and Amikacin combination as a potent and efficacious therapy for febrile neutropenia patients with haematological malignancies. However, continuous surveillance remains prudent for the emerging changes in the spectrum and resistance pattern of local flora so that timely revision of empirical antibiotic regimens can save the added financial burdens and associated high morbidity and mortality.

Keywords

Febrile neutropenia Microbiological spectrum Antibiotic sensitivity Haematological malignancies Microbiologically documented infections 

Notes

Authors’ Contribution

AJ conceptualized and investigated the study and wrote the manuscript. NF and BK performed the statistical analysis. QR, UZ and MB played their part in searching literature and supervision of project. TS and SS supervised the study and critically reviewed the manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

This study was approved by the Institutional Review Board and informed consent was taken from the participants prior to the study.

Supplementary material

12088_2019_789_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 19 kb)

References

  1. 1.
    Babady NE (2016) Laboratory diagnosis of infections in cancer patients: challenges and opportunities. J Clin Microbiol 54:2635–2646.  https://doi.org/10.1128/JCM.00604-16 CrossRefGoogle Scholar
  2. 2.
    Karimi F, Ashrafi F, Moghaddas A, Derakhshandeh A (2018) Management of febrile neutropenia: a description of clinical and microbiological findings by focusing on risk factors and pitfalls. J Res Pharm Pract 7:147–156.  https://doi.org/10.4103/jrpp.JRPP_18_16 CrossRefGoogle Scholar
  3. 3.
    Tai E, Guy GP, Dunbar A, Richardson LC (2017) Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract 13:e552–e561.  https://doi.org/10.1200/JOP.2016.019588 CrossRefGoogle Scholar
  4. 4.
    Kapoor R, Simalti AK, Roy S, Agarwal P (2018) Clinicohematological profile of febrile neutropenia in childhood acute leukemia and utility of serum procalcitonin levels in neutropenic patients. Indian J Crit Care Med 22:336–339.  https://doi.org/10.4103/ijccm.IJCCM_516_17 CrossRefGoogle Scholar
  5. 5.
    Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G (2008) Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61:721–728.  https://doi.org/10.1093/jac/dkm514 CrossRefGoogle Scholar
  6. 6.
    Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C (2014) Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol 27:1–9.  https://doi.org/10.1155/2014/986938 CrossRefGoogle Scholar
  7. 7.
    Gustinetti G, Mikulska M (2016) Bloodstream infections in neutropenic cancer patients: a practical update. Virulence 7:280–297.  https://doi.org/10.1080/21505594.2016.1156821 CrossRefGoogle Scholar
  8. 8.
    Babu KG, Lokanatha D, Lakshmaiah KC, Babu MS, Jacob LA, Bhat GR, Vardhana H, Sinha M, Vijaykumar BR, Sumati BG, Jayshree RS (2016) Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: a timeline of clinical and microbial trends through the years. Ind J Med Paediatr Oncol 37:174–182.  https://doi.org/10.4103/0971-5851.190352 CrossRefGoogle Scholar
  9. 9.
    Sharma A, Lokeshwar N (2005) Febrile neutropenia in haematological malignancies. J Postgrad Med 51:S42–S48Google Scholar
  10. 10.
    Perez F, Adachi J, Bonomo RA (2014) Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis 59:S335–S339.  https://doi.org/10.1093/cid/ciu612 CrossRefGoogle Scholar
  11. 11.
    Demirel A, Tabak F, Ar MC, Mete B, Öngören Ş, Yemişen M, Özaras R, Eşkazan E, Başlar Z, Mert A, Soysal T (2015) Secondary infections in febrile neutropenia in hematological malignancies: more than another febrile neutropenic episode. Turk J Haematol 32:243–250.  https://doi.org/10.4274/tjh.2013.0422 CrossRefGoogle Scholar
  12. 12.
    De Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F (2010) ESMO Guidelines Working Group. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21:v252–v2566.  https://doi.org/10.1093/annonc/mdq196 CrossRefGoogle Scholar
  13. 13.
    Taj ME, Farzana T, Shah T, Maqsood S, Ahmed SS, Shamsi TS (2015) Clinical and microbiological profile of pathogens in febrile neutropenia in hematological malignancies: a single center prospective analysis. J Oncol 2015:1–5.  https://doi.org/10.1155/2015/596504 CrossRefGoogle Scholar
  14. 14.
    Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40:S240–S245.  https://doi.org/10.1086/427329 CrossRefGoogle Scholar
  15. 15.
    Karanwal AB, Parikh BJ, Goswami P, Panchal HP, Parekh BB, Patel KB (2013) Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: a retrospective analysis from a single center. Ind J Med Paediatr Oncol 34:85–88.  https://doi.org/10.4103/0971-5851.116184 CrossRefGoogle Scholar
  16. 16.
    Yadegarynia D, Fatemi A, Mahdizadeh M, Movahhed RK, Alizadeh MA (2013) Current spectrum of bacterial infections with nosocomial fever and neutropenia. Caspian J Inter Med 4:698Google Scholar
  17. 17.
    Sirkhazi M, Sarriff A, Aziz NA, Almana F, Arafat O, Shorman M (2014) Bacterial spectrum, isolation sites and susceptibility patterns of pathogens in adult febrile neutropenic cancer patients at a specialist Hospital in Saudi Arabia. World J Oncol 5:196–203.  https://doi.org/10.14740/wjon850w CrossRefGoogle Scholar
  18. 18.
    Lakshmaiah KC, Malabagi AS, Govindbabu RS, Sinha M, Jayashree RS (2015) Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Physicians 7:116–120.  https://doi.org/10.4103/0974-2727.163126 CrossRefGoogle Scholar
  19. 19.
    Mandal PK, Maji SK, Dolai TK, De R, Dutta S, Saha S, Bhattacharyya M (2015) Micro-organisms associated with febrile neutropenia in patients with haematological malignancies in a tertiary care hospital in Eastern India. Ind J Hematol Blood Transfus 31:46–50.  https://doi.org/10.1007/s12288-014-0393-1 CrossRefGoogle Scholar
  20. 20.
    Görük M, Dal MS, Dal T, Karakus A, Tekin R, Özcan N, Ayyildiz O (2015) Evaluation of febrile neutropenic patients hospitalized in a hematology clinic. Asian Pac J Trop Biomed 5:1051–1054.  https://doi.org/10.1016/j.apjtb.2015.09.014 CrossRefGoogle Scholar
  21. 21.
    Sacar S, Hacioglu SK, Keskin A, Turgut H (2008) Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey. J Inf Dev Ctries 2:359–363.  https://doi.org/10.3855/jidc.197 Google Scholar
  22. 22.
    Lima SS, Franca MS, LA MartinhoGH Jesus, Romanelli RMC, Clemente WT (2013) Neutropenic patients and their infectious complications at a University Hospital. Rev Bras Hematol Hemoter 35:18–22.  https://doi.org/10.5581/1516-8484.20130009 CrossRefGoogle Scholar
  23. 23.
    Shamsi TS, Farzana T, Ansari SH, Ahmed A, Ishaque A (2003) Febrile neutropenia in haematological disorders: a single centre review of antibiotic policy and the outcome. J Pak Med Assoc 53:190–193Google Scholar
  24. 24.
    Ansari SH, Nasim S, Ahmed A, Irfan M, Ishaque A, Farzana T, Panjwani VK, Taj M, Shamsi TS (2006) Febrile neutropenia in paediatric peripheral blood Stem cell transplantation, in -vitro sensitivity data And clinical response to empirical antibiotic Therapy. J Coll Phys Surg Pak 16:704–708Google Scholar
  25. 25.
    Ghalaut PS, Chaudhary U, Ghalaut VS, Dhingra A, Dixit G, Aggarwal S (2011) Piperacillin-tazobactum plus Amikacin versus ceftazidime plus Amikacin as empirical therapy for fever in neutropenic patients with hematological malignancies. Ind J Hematol Blood Transfus 27:131–135.  https://doi.org/10.1007/s12288-011-0076-0 CrossRefGoogle Scholar

Copyright information

© Association of Microbiologists of India 2019

Authors and Affiliations

  1. 1.Department of Clinical Haematology and BMTNational Institute of Blood Disease & Bone Marrow TransplantationKarachiPakistan
  2. 2.Department of Clinical Research & DevelopmentNational Institute of Blood Disease & Bone Marrow TransplantationKarachiPakistan
  3. 3.Department of MicrobiologyNational Institute of Blood Disease & Bone Marrow TransplantationKarachiPakistan

Personalised recommendations